Zevra Therapeutics: Promising Growth Driven by Miplyffa Success and Strategic Focus on Rare Diseases

In a report released yesterday, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Zevra Therapeutics, with a price target of $25.00.

Sumant Kulkarni has given his Buy rating due to a combination of factors related to Zevra Therapeutics’ promising developments and market performance. The company has experienced a notable increase in its stock value, largely driven by the successful launch and sales ramp of Miplyffa, a treatment for Niemann-Pick Type C disease. This product’s sales momentum is expected to continue, with further growth anticipated as the company prepares for a European filing.
Additionally, Zevra’s strategic focus on rare diseases is gaining recognition, with potential upside from other products in its pipeline. The company’s efforts in advancing treatments for urea cycle disorders and vascular Ehlers-Danlos syndrome, along with ongoing research in idiopathic hypersomnia, highlight its commitment to addressing unmet medical needs. Despite some uncertainties in quarterly sales predictions, the company’s robust financial position and strategic initiatives support the positive outlook reflected in the Buy rating.

In another report released on July 9, Cantor Fitzgerald also maintained a Buy rating on the stock with a $29.00 price target.

ZVRA’s price has also changed dramatically for the past six months – from $8.050 to $12.660, which is a 57.27% increase.